Immunocore Holdings (IMCR)
NASDAQ:IMCR
IMCR Stock Chart & Stats
$30.51
-$0.07(-0.21%)
At close: 4:00 PM EST
$30.51
-$0.07(-0.21%)
Day’s Range― - ―
52-Week Range$23.15 - $40.71
Previous CloseN/A
Volume28.13K
Average Volume (3M)358.92K
Market Cap
$1.55B
Enterprise Value$1.12B
Total Cash (Recent Filing)$864.15M
Total Debt (Recent Filing)$43.56M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
May 13, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding50,695,080
10 Day Avg. Volume338,864
30 Day Avg. Volume358,918
Financial Highlights & Ratios
PEG Ratio1.38
Price to Book (P/B)4.59
Price to Sales (P/S)5.87
P/FCF Ratio-156.07
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue3.01
Enterprise Value/Gross Profit3.05
Enterprise Value/Ebitda-3.46K
Forecast
1Y Price Target
$65.75Price Target Upside115.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.92
Revenue Forecast (FY)$448.19M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutAn on-track Phase 3 TEBE-AM program with a pivotal overall survival readout could meaningfully expand the eligible patient population and drive upside if results are positive.
Commercial UptakeBroad adoption of KIMMTRAK in community clinics combined with longer patient treatment durations supports steady revenue generation and reinforces its role as the standard of care in metastatic uveal melanoma.
Pipeline DiversificationMultiple late-stage programs across oncology, infectious disease, and autoimmune indications, including a PRAME asset, provide several distinct opportunities to add value beyond the lead product.
Bears Say
Clinical And Competitive RiskDependence on a small number of late-stage trials leaves future performance vulnerable to unfavorable readouts or positive data from competing therapies that could dent investor confidence and forecasts.
Market SaturationHigh penetration in the uveal melanoma patient population and a moderate market size limit organic growth potential for KIMMTRAK, capping near-term upside.
Revenue Growth ModerationManagement guidance pointing to moderating revenue growth as penetration deepens implies slower sales expansion and reduced earnings momentum compared with earlier launch phases.
Immunocore Holdings News
IMCR FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was $23.15 and its highest was $40.71 in the past 12 months.
What is Immunocore Holdings’s market cap?
Immunocore Holdings’s market cap is $1.55B.
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is May 13, 2026 which is in 47 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on Nov 06, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.232 by $0.232.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -0.27.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 50,695,080 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of $0 in its last earnings report, beating expectations of -$0.232. Following the earnings report the stock price went up 2.597%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Currently, no hedge funds are holding shares in IMCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunocore Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.75 (115.50% Upside)
$65.75 (115.50% Upside)
Blogger Sentiment
Bullish
IMCR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 357.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.27%
12-Months-Change
Fundamentals
Return on Equity
-6.93%
Trailing 12-Months
Asset Growth
5.72%
Trailing 12-Months
Company Description
Immunocore Holdings
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
IMCR Stock 12 Month Forecast
Average Price Target
$65.75
▲(115.50% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---